BX vs LGND: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BX and LGND share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BX and LGND exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Blackstone Inc. is the world's largest alternative asset manager, investing on behalf of pension funds, sovereign wealth funds, insurers, endowments, and increasingly individual investors. It runs money across several major strategies: real estate (historically its largest), private equity, credit and insurance, infrastructure, life sciences, growth equity, secondaries, and hedge fund solutions. The business model has two engines. First, it earns recurring management fees on the capital it manages, which produces relatively stable fee-related earnings and grows as assets under management climb. Second, it earns performance fees (carried interest and incentive fees) when its funds generate strong returns, which are lumpier and depend on realizations and market conditions. Because most of its capital is locked up in long-dated funds, Blackstone has durable, contracted fee streams, and it distributes a large share of its distributable earnings to shareholders as a variable quarterly dividend rather than a fixed one.

Full BX guide

Ligand Pharmaceuticals earns money three ways, and only one of them looks like a normal drug company. Royalties on partnered medicines were ~$48.0M of the ~$63.7M reported in the June 2026 quarter, split between rights carried as intangible royalty assets (Filspari at ~$13.6M, Kyprolis ~$7.0M, Ohtuvayre ~$4.1M, Rylaze ~$3.2M, plus Capvaxive, Vaxneuvance and teriparatide) and financial royalty assets accounted for more like loans (Qarziba ~$6.2M, an Ohtuvayre inventors stream ~$3.3M). Captisol, a modified cyclodextrin that makes poorly soluble injectable drugs formulable and sits inside products such as Amgen's Kyprolis and Baxter's Nexterone, added ~$8.0M of material sales. Contract revenue and milestone income supplied the remaining ~$7.7M. Ligand runs no salesforce and no manufacturing plant for the drugs it collects on, which is the whole point of the structure.

Full LGND guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BX drivers: Growth of assets under management; Private wealth and retail channel.
• LGND drivers: The royalty line is compounding, not just holding; XOMA Royalty more than doubled the portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Blackstone's risks stem from its market-linked, cyclical model. For LGND, ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BX if you believe its drivers more; LGND if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BX and LGND guides.

BX. These figures are qualitative and approximate as of the asOf date, not precise real-time numbers. Because performance fees and the variable dividend move with realizations and markets, quarterly results can be uneven. Confirm live AUM, revenue, fee-related earnings, dividend, and valuation before acting.

LGND. A sales multiple is close to meaningless for a royalty book, because royalty revenue carries essentially no cost of goods and the expense base is an office of dealmakers rather than a commercial organisation. Measured against guided 2026 adjusted earnings of ~$9.00 to ~$9.50, the stock sits near ~31x, and management points to operating cash flow above ~$200M this year and around ~$300M next. What that price embeds is an assumption that fresh royalty purchases keep arriving at accretive terms.

Headline figures (approximate, Jul 2026): BX shows assets under management More than $1.3 trillion as of early 2026, the largest of any alternative asset manager, after record inflows (roughly $70 billion in a recent quarter), revenue trend Full-year 2025 revenue was about $14.5 billion, up roughly $1.2 billion year over year; management and advisory fees were about $8.1 billion, profitability Emphasizes fee-related earnings (recurring management fees) as the stable core, with performance fees (carried interest) adding lumpier upside tied to realizations, capital returns Pays a variable quarterly dividend tied to distributable earnings (not a fixed rate) plus buybacks, so the payout rises and falls with results; LGND shows revenue (ttm) ~$291M, up ~55%, royalty revenue (q2 2026) ~$48.0M, up ~32% year over year, net income (ttm) ~$197M, about ~$9.19 per share, fy2026 guidance revenue ~$270M to ~$310M, adjusted EPS ~$9.00 to ~$9.50.

BX and LGND are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BX and LGND exposure against your real portfolio. It is not an investment adviser.